Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:EWTX News 18 December 2025 - 30 December 2025

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

NEW YORK, December 30, 2025, 12:33 ET — Regular session Edgewise Therapeutics shares were up 0.2% at $24.68 as of 12:18 p.m. ET on Tuesday, after a Form 144 filing showed company officer Robert Michael Carruthers sold 116,665 shares worth about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92. SEC The disclosure matters because Edgewise is a development-stage biotech, where trading often centers on clinical milestones and cash runway rather than product sales. Insider transactions can draw outsized attention after sharp moves, even when the dollar amounts are modest. Biotech stocks also lagged, with the iShares
30 December 2025
·····
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

NEW YORK — Friday, December 26, 2025 (1:07 p.m. ET). U.S. stocks are trading in a post-holiday session with major benchmarks close to flat, while biotech is notably weaker. Against that backdrop, Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is pulling back after a sharp midweek move tied to a clinical update in hypertrophic cardiomyopathy (HCM). As of the latest trade captured around 12:55 p.m. ET, EWTX traded near $26.00, down about 4.7% on the day, with an intraday range of $25.40 to $27.92 and volume above 1.0 million shares. EWTX price action in today’s market: biotech pressure meets profit-taking Today’s tape
26 December 2025
·····
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. stock exchanges have not yet opened for the regular session (standard hours are 9:30 a.m. to 4:00 p.m. ET). Nasdaq Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is in focus heading into the post-holiday session after the company delivered an encouraging clinical update for EDG-7500—its investigational therapy for hypertrophic cardiomyopathy (HCM)—that helped drive a sharp rally in the last session before Christmas. PR Newswire Where EWTX stock stands pre-market Market data tracked by MarketBeat shows EWTX closing at $27.38 on December 24 (the last regular session before Christmas
26 December 2025
·····
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

December 22, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight as its stock price whipsaws following a sharp late-week surge and a fresh round of market commentary that mixes optimism about the company’s muscle-disease pipeline with familiar concerns about cash burn in a pre-revenue biotech. As of 18:40 UTC on Dec. 22, EWTX traded at $21.29, after swinging between $27.77 and $21.18 intraday, with volume running well above a million shares. Below is a complete, news-style breakdown of the current coverage and forecasts circulating on Dec. 22, 2025, plus the trial and business milestones investors are
22 December 2025
·····
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight heading into December 20, 2025—not because of a single blockbuster headline, but because the stock just posted a sharp, high-volume move that traders and long-term biotech investors both tend to notice. With Edgewise still a clinical-stage company, the share price often reflects a shifting mix of (1) expectations for clinical readouts, (2) perceived regulatory timelines, and (3) sentiment in the biotech tape. In other words: EWTX can move fast—even when the company itself hasn’t issued fresh news in the last 24–48 hours. Below is a comprehensive look at the latest
21 December 2025
····
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is ending mid-December 2025 in classic clinical-stage biotech fashion: big percentage swings, a sharp momentum breakout, and investors trying to decide whether the move is “new information” or simply “new positioning.” As of Saturday, December 20, 2025, EWTX is being widely quoted around $25.55—a level reached after a powerful jump in the prior U.S. session. StockAnalysis+1 What matters for readers tracking the stock isn’t just the price print. It’s the why: a late-stage neuromuscular story (sevasemten), a closely watched cardiovascular program (EDG-7500), and a pipeline that can re-rate quickly on clinical updates—up or down. PR
20 December 2025
···
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

December 18, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) saw its shares slide sharply in Thursday trading, a reminder that clinical-stage biotech stocks can move fast even when there’s no single headline screaming for attention. EWTX finished the session around $20.35, down roughly 8.8% from the prior close, after trading between about $20.33 and $22.81. StockAnalysis That drop matters because the Edgewise story is still mostly about future clinical readouts and regulatory path clarity, not current product revenue. The company is advancing late-stage work in muscular dystrophies (with its lead program, sevasemten) and also developing cardiac sarcomere modulators for conditions
18 December 2025
·····

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop